The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct ...

Objective: To quantitate the separate impact of obesity and hyperlycemia on the incretin effect (i.e., the gain in β-cell function after oral glucose versus intravenous glucose). Research Design ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

The effects of SGLT2 inhibitors on the kidney to prevent progression of chronic kidney disease, congestive heart failure, ...

reducing food intake and having trophic effects on the pancreatic islet cells. [9] These incretin hormones have been implicated recently in the pathogenesis of Type 2 diabetes. GLP-1 is ...

Eli Lilly LLY2.29%increase; green up pointing triangle cut its outlook for fourth-quarter revenue as the market for drugs that increase insulin levels grew slower than expected, but the company ...

Rising prevalence of diabetes, recent product approvals & product launches in the market are the major factors driving the market for incretin-based drugs.

Novo Nordisk's amycretin trial results highlight significant weight loss in adults with obesity, with further clinical ...

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

The effects of the formulation were comparable to the results observed for the marketed subcutaneous formulation. This nanocarrier-based strategy represents a novel promising approach for oral peptide ...